Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KYMR Kymera Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: KYMR
Price (delayed)
$44.26
Market cap
$2.88B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.11
Enterprise value
$2.87B
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein
Highlights
KYMR's gross profit is down by 26% year-on-year but it is up by 25% since the previous quarter
KYMR's revenue is down by 26% YoY but it is up by 25% from the previous quarter
KYMR's net income has dropped by 56% year-on-year and by 8% since the previous quarter
The company's EPS fell by 24% YoY and by 4.4% QoQ
Key stats
What are the main financial stats of KYMR
Market
Valuations
Earnings
Shares outstanding
65.12M
Market cap
$2.88B
Enterprise value
$2.87B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.66
Price to sales (P/S)
60.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.79
Revenue
$58.89M
Gross profit
$58.89M
Operating income
-$278.23M
Net income
-$240.88M
EBIT
-$240.63M
EBITDA
-$232.67M
Free cash flow
-$239.96M
Per share
Balance sheet
Liquidity
EPS
-$3.11
EPS diluted
-$3.11
Free cash flow per share
-$2.99
Book value per share
$12.11
Revenue per share
$0.73
TBVPS
$11.46
Total assets
$918.31M
Total liabilities
$132.08M
Debt
$86.33M
Equity
$786.23M
Working capital
$441.96M
Debt to equity
0.11
Current ratio
8.49
Quick ratio
7.95
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-395.1%
Gross margin
100%
Net margin
-409.1%
Operating margin
-472.5%
Return on assets
-25.6%
Return on equity
-30.1%
Return on invested capital
-28%
Return on capital employed
-28%
Return on sales
-408.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYMR stock price
How has the Kymera Therapeutics stock price performed over time
Intraday
1.56%
1 week
53.68%
1 month
25.45%
1 year
38.57%
YTD
10.02%
QTD
61.71%
Financial performance
How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$58.89M
Gross profit
$58.89M
Operating income
-$278.23M
Net income
-$240.88M
Gross margin
100%
Net margin
-409.1%
The operating margin has plunged by 111% YoY but it has grown by 15% from the previous quarter
KYMR's net margin has dropped by 110% year-on-year but it is up by 14% since the previous quarter
KYMR's net income has dropped by 56% year-on-year and by 8% since the previous quarter
The company's operating income has shrunk by 56% YoY and by 6% QoQ
Price vs fundamentals
How does KYMR's price correlate with its fundamentals
Growth
What is Kymera Therapeutics's growth rate over time
Valuation
What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
3.66
P/S
60.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.79
The company's EPS fell by 24% YoY and by 4.4% QoQ
The stock's price to book (P/B) is 31% more than its last 4 quarters average of 2.8 but 15% less than its 5-year quarterly average of 4.3
The equity has grown by 11% YoY but it has contracted by 6% from the previous quarter
The price to sales (P/S) is 84% higher than the 5-year quarterly average of 32.8 and 44% higher than the last 4 quarters average of 41.8
KYMR's revenue is down by 26% YoY but it is up by 25% from the previous quarter
Efficiency
How efficient is Kymera Therapeutics business performance
The company's return on sales has shrunk by 110% YoY but it rose by 14% QoQ
KYMR's return on assets is down by 7% year-on-year and by 6% since the previous quarter
The company's return on equity rose by 6% YoY but it fell by 4.9% QoQ
The return on invested capital has declined by 6% since the previous quarter and by 3.7% year-on-year
Dividends
What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYMR.
Financial health
How did Kymera Therapeutics financials performed over time
The total liabilities has contracted by 16% YoY and by 7% from the previous quarter
Kymera Therapeutics's quick ratio has decreased by 15% YoY but it has increased by 9% QoQ
KYMR's debt is 89% smaller than its equity
The equity has grown by 11% YoY but it has contracted by 6% from the previous quarter
Kymera Therapeutics's debt to equity has decreased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.